Barcelona Liver Bioservices announces collaboration with GAT Therapeutics

Barcelona Liver Bioservices, CRO specialized in the design and development of pre-clinical studies in the field of liver diseases, announced today a non-exclusive collaboration with GAT Therapeutics, an early stage biopharma targeting fibrosis and age-related diseases.

Under the terms of the agreement, BLB will deeply characterize the effects of GATTx’s lead compound GTX-011 on non-alcoholic steatohepatitis (NASH), liver cirrhosis and portal hypertension. The research plan incorporates different BLB’s proprietary methods & technology, including the BarNa model®, unique pre-clinical model of NASH that mimics key pathophysiological and transcriptomic features of the human disease, and the exclusive ExoLiver® platform, BLB’s advanced model of human liver disease.

BLB aims at providing valuable insights into complex disease pathways and drug responses in a more meaningful liver disease pre-clinical context. For more information please visit

More News

Barcelona Liver Bioservices (BLB) starts operations

Barcelona Liver Bioservices (BLB), a spin-off of IDIBAPS, has been created for the design and development of pre-clinical studies in the fields of hepatology and hepatotoxicity. The co-founders are Jordi Gracia-Sancho, Jaume Bosch and Joan Carles Garcia-Pagan from IDIBAPS and Rosa Villa from CSIC.

Read More »